California Public Employees Retirement System Sells 4,681 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

California Public Employees Retirement System lowered its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 2.8% during the 4th quarter, Holdings Channel reports. The fund owned 164,712 shares of the biopharmaceutical company’s stock after selling 4,681 shares during the period. California Public Employees Retirement System’s holdings in Intra-Cellular Therapies were worth $13,757,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ITCI. GAMMA Investing LLC raised its position in shares of Intra-Cellular Therapies by 46.3% during the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Intra-Cellular Therapies in the fourth quarter valued at $96,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Intra-Cellular Therapies during the third quarter valued at about $97,000. Quarry LP increased its position in shares of Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth about $184,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ITCI. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler restated a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. StockNews.com assumed coverage on Intra-Cellular Therapies in a research note on Saturday. They set a “hold” rating on the stock. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Hold” and an average target price of $106.23.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock opened at $131.87 on Friday. The firm has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The company has a 50 day moving average of $129.62 and a 200-day moving average of $101.61. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.